Analysts’ Weekly Ratings Updates for Spyglass Pharma (SGP)

Several brokerages have updated their recommendations and price targets on shares of Spyglass Pharma (NASDAQ: SGP) in the last few weeks:

• 3/3/2026 – Spyglass Pharma was downgraded by Leerink Partners to “market perform”.
• 3/3/2026 – Spyglass Pharma is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $62.00 price target on the stock.
• 3/3/2026 – Spyglass Pharma is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $62.00 price target on the stock.
• 3/3/2026 – Spyglass Pharma is now covered by Citigroup Inc.. They set a “buy” rating and a $42.00 price target on the stock.
• 3/3/2026 – Spyglass Pharma is now covered by Leerink Partners. They set an “outperform” rating and a $42.00 price target on the stock.
• 3/3/2026 – Spyglass Pharma is now covered by Stifel Nicolaus. They set a “buy” rating and a $42.00 price target on the stock.
• 2/17/2026 – Spyglass Pharma was upgraded by Wall Street Zen to “hold”.

Insiders Place Their Bets

In related news, Director Ra Capital Management, L.P. purchased 3,690,000 shares of Spyglass Pharma stock in a transaction that occurred on Monday, February 9th. The stock was purchased at an average cost of $16.00 per share, with a total value of $59,040,000.00. Following the completion of the transaction, the director directly owned 5,966,439 shares in the company, valued at approximately $95,463,024. The trade was a 162.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).